VEGFA and glioblastoma: Hence, low dose of VEGF-targeted therapy in association with Ang-2-targeted treatment has been proposed to overcome resistance to antiangiogenic therapies by regulating GBM barrier permeability and modulating the pro-tumorigenic effects of endothelial cell destruction [28].